__timestamp | Catalent, Inc. | Ultragenyx Pharmaceutical Inc. |
---|---|---|
Wednesday, January 1, 2014 | 334800000 | 10811000 |
Thursday, January 1, 2015 | 337300000 | 33001000 |
Friday, January 1, 2016 | 358100000 | 64936000 |
Sunday, January 1, 2017 | 402600000 | 99909000 |
Monday, January 1, 2018 | 462600000 | 127724000 |
Tuesday, January 1, 2019 | 512000000 | 161524000 |
Wednesday, January 1, 2020 | 577900000 | 182933000 |
Friday, January 1, 2021 | 687000000 | 219982000 |
Saturday, January 1, 2022 | 844000000 | 278139000 |
Sunday, January 1, 2023 | 831000000 | 309799000 |
Monday, January 1, 2024 | 935000000 |
Unleashing the power of data
In the competitive landscape of the pharmaceutical and biotech industries, understanding the financial strategies of key players is crucial. Catalent, Inc. and Ultragenyx Pharmaceutical Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Catalent's SG&A expenses have surged by approximately 179% over this period, reflecting a strategic expansion and investment in operational capabilities. In contrast, Ultragenyx's expenses have increased by nearly 2,765%, indicating a rapid scale-up in its business operations, albeit from a smaller base.
Catalent's consistent growth in SG&A expenses suggests a steady scaling of operations, while Ultragenyx's sharp rise points to aggressive growth strategies. The data for 2024 is incomplete, highlighting the need for ongoing analysis to understand future trends. Investors and industry analysts should consider these financial trajectories when evaluating the companies' market positions.
Comparing SG&A Expenses: AbbVie Inc. vs Catalent, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Ultragenyx Pharmaceutical Inc.
Zoetis Inc. and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Biogen Inc. and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Genmab A/S vs Catalent, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Walgreens Boots Alliance, Inc.
Breaking Down SG&A Expenses: Catalent, Inc. vs Veracyte, Inc.
Axsome Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
Ultragenyx Pharmaceutical Inc. vs ImmunityBio, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Ultragenyx Pharmaceutical Inc. and Soleno Therapeutics, Inc.